IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient
The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte's experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study's first part, the companies announced. It also dosed the first patient in the trial's second part. "Completion of the Phase 1b enrollment and initiation of the Phase 2 component of our clinical program are key milestones in our goal to accelerate the clinical evaluation and path to market of our novel immuno-therapy,” Frederic Ors, the CEO of IMV, said in a press release. “We are very pleased to be able to continue to make substantial progress for advanced ovarian cancer patients who have such a high unmet medical need,” he added. DPX-Survivac consists of small fractions of the survivin protein, which is broadly over-activated in most cancer types and promotes tumor growth, according to IMV. Survivin plays an essential role in supporting tumor blood vessel growth and promoting resistance to anti-cancer therapies. The therapy, administered as an injection under the skin, works by triggering a strong immune response against cancer cells producing the survivin protein, causing them to die. Epacadostat is a potent, selective oral IDO1 inhibitor. Belonging to the growing class of checkp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *